

Only for use in NHL



Educational Material

Step by Step Guide

MabThera SC 1,400 mg is indicated in adults for non-Hodgkin's lymphoma (NHL):*

- For the treatment of previously untreated patients with stage III–IV follicular lymphoma (FL) in combination with chemotherapy
- As maintenance therapy for the treatment of patients with FL responding to induction therapy
- For the treatment of patients with CD20-positive diffuse large B-cell NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy.

MabThera 1,400 mg is only for subcutaneous use in NHL.

The recommended dose of MabThera subcutaneous formulation used for adult patients is a subcutaneous injection at a fixed dose of 1400 mg irrespective of the patient's body surface area.

This leaflet has been produced by Roche for physicians, nurses and pharmacists for the safe and efficient use of MabThera solution for subcutaneous injection (referred to as MabThera SC) in patients with CLL and NHL.

Supply, storage and handling of MabThera SC*

How MabThera SC is supplied:


- Each carton contains one glass vial
- Each vial contains a sterile, non-pyrogenic and preservative-free solution (extractable volume is equivalent to one dose for administration to the patient) of:

— 11.7 ml (1,400 mg) for NHL

- The solution is clear to opalescent, colourless to yellowish. Do not use if you notice unusual coloration or presence of visible particles.
- Composition:
 - The active ingredient of MabThera SC is rituximab.
 - The excipients are:
 - Recombinant human hyaluronidase (rHuPH20): this is an enzyme used to increase the dispersion and absorption of co-administered drugs when administered subcutaneously. It allows the injection of larger volumes via the subcutaneous route.
 - Other excipients: L-histidine, L-histidine hydrochloride monohydrate, α,α -trehalose dihydrate, L-methionine, polysorbate 80 and water for injections.
 - The pH of the solution is between 5 and 6.

How MabThera SC should be stored:

- Keep the vial in the outer carton to protect MabThera SC from light.
- Store MabThera SC in a refrigerator (2–8°C). DO NOT FREEZE.
- Check the expiry date on the outer carton.



How to handle MabThera SC:

- Before handling MabThera SC, please check the packaging to ensure you have the correct formulation and strength: all have different colour packaging.
- MabThera SC does not contain any antimicrobial preservative and, as with all unpreserved sterile solutions, should be used immediately.
- No incompatibilities have been observed between MabThera SC and the following: polypropylene or polycarbonate syringe material, stainless steel transfer and injection needles, polyethylene Luer cone stoppers.

Check for the specific MabThera SC packaging characteristics

Please refer to the comparison card for further detail

How to administer MabThera SC: step-by-step guide*

Important reminder:

- All patients must receive beforehand a full dose of MabThera by intravenous infusion, using MabThera intravenous formulation. The switch to MabThera subcutaneous formulation can only occur at the second or subsequent cycle of treatment.*
- Premedication consisting of an anti-pyretic and an anti-histaminic, e.g. paracetamol and diphenhydramine, should always be given before each administration of MabThera. Premedication with glucocorticoids should be considered if MabThera is not given in combination with glucocorticoid- containing chemotherapy.
- MabThera SC should be administered in an environment where full resuscitation facilities are immediately available and under the close supervision of an experienced healthcare professional.

1. Prepare the patient for injection

- The patient should be asked to lean back in a reclining chair or a bed and to make their abdominal region accessible for injection.



2. Prepare the injection site

- The selected abdominal site should be thoroughly disinfected as per local practice.
- Each injection should be given at a different site and never into areas where the skin is red, bruised, tender, hard, or into areas where there are moles or scars.



3. Prepare MabThera SC for injection

- The syringe should be prepared at the time of its administration.
- Ensure use of a needle suitable for subcutaneous injection.
- Attach the hypodermic injection needle to the syringe immediately prior to administration to avoid potential needle clogging.
- The whole content of the vial should be injected:

— 11.7 ml (1,400 mg) for NHL

4. Perform the injection

- Pinch the skin of the abdomen with one hand to create a skin fold: this will facilitate the injection.
- Insert the injection needle into the skin fold with the other hand, using a sterile technique.
- Release the skin fold and apply pressure on the syringe, slowly injecting MabThera SC into the subcutaneous tissue.
- MabThera SC should be administered over approximately 7 minutes
 - Using the palm of the hand to depress the plunger can help to maintain a constant flow rate.
 - Ensure the full content of the syringe is injected into the subcutaneous tissue.
- After application, the injection site may be covered with a dressing, as per locally approved protocol.



5. Inform the patient that they may leave

- The patient should be observed for at least 15 minutes following MabThera SC administration. A longer period of observation may be appropriate in patients with an increased risk of hypersensitivity reactions.
- If the patient is not receiving any further treatment
- after the MabThera SC injection, and if the patient is not presenting with any adverse reaction to the injection, the patient may leave the clinic.
- Many patients experience some side effects at or around the MabThera SC injection site. These local side effects include pain, swelling, induration, bleeding, skin redness, itching and rash.
- The patient should be instructed to contact their doctor immediately if the following symptoms occur: breathing difficulties, tongue or throat swelling, vomiting or palpitations, as they could be indicative of an allergic reaction.



Further information

In case of any adverse events – including any possible side effects not listed in the leaflet – or product complaints associated with the use of any Roche products, please talk to the HCP or report the details in accordance with the national requirements via the national spontaneous reporting systems to:



The National Pharmacovigilance Centre (NPC)
Land Line: 19999.
Fax: +966112057662
Email: npc.drug@sfd.gov.sa

Roche Products Saudi Arabia L.L.C.
Direct Tel. +966 12211 4618
Mobile: +966 5678 44 692
Email: jeddah.drug_safety@roche.com

Company contact point

Should you have any questions regarding the use of ROCHE PRODUCT, please feel free to contact us at jeddah.medinfo@roche.com

Roche Products Saudi Arabia



This document has been reviewed and approved by The Saudi Food and Drug Authority (SFDA)